Marcus JL, et al. - A comparative evaluation was performed of the effectiveness of 8 vs 12 weeks of the combination of ledipasvir and sofosbuvir in black patients who were otherwise eligible for an 8-week treatment regimen for the treatment of hepatitis C. No statistically marked variations were reported in sustained virologic response 12 weeks after the end of treatment (SVR12) due to 8-week and 12-week treatment regimens among black patients. Data shed light on the connection between patient characteristics with receipt of 12-week regimens among patients eligible for 8 weeks. However, these were not linked with reduced SVR12 after 8 weeks. Hence, a more widespread use of shorter treatment courses could be recommended without compromising treatment effectiveness.